PDCD1 and cutaneous melanoma: The response rates observed in the present study were close to those reported in previous series of MM patients treated with anti-CTLA-4 or anti-PD-1 mAbs, which ranged between 7% and 12% with anti-CTLA-4 [19, 20] and between 19% and 23% with anti-PD-1 mAbs [21, 25–27], but which were lower than response rates reported in cutaneous melanoma [13].